Safety and clinical activity of oleclumab (O) ± durvalumab (D) plus chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study

被引：0
|
作者：
Coveler, Andrew L.
Reilley, Matthew
Zalupski, Mark
Macarulla, Teresa
Fountzilas, Christos
Castanon Alvarez, Eduardo
Nagrial, Adnan
Volodymyrivna Uboha, Nataliya
Frentzas, Sophia
Overman, Michael J.
Noonan, Anne M.
Messersmith, Wells A.
Pavlakis, Nick
Mettu, Niharika B.
Smith, Paul
Murtomaki, Elina
Bragulat, Veronique
Cooper, Zachary A.
Kumar, Rakesh
Spigel, David
机构：
[1] Fred Hutchinson Canc Ctr, Seattle, WA USA
[2] Univ Virginia, Ctr Comprehens Canc, Charlottesville, VA USA
[3] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[4] Hosp Univ Vall DHebron, Barcelona, Spain
[5] Roswell Pk Canc Inst, Buffalo, NY USA
[6] Clin Univ Navarra, Madrid, Spain
[7] Blacktown Hosp, Sydney, NSW, Australia
[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[9] Monash Hlth Monash Med Ctr, Clayton, Vic, Australia
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[11] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
[12] Univ Colorado, Denver, CO USA
[13] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia
[14] Duke Univ, Med Ctr, Durham, NC USA
[15] AstraZeneca, Cambridge, England
[16] AstraZeneca, Gaithersburg, MD USA
[17] Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)
    Bekaii-Saab, T.
    Starodub, A.
    El-Rayes, B.
    O'Neil, B.
    Shahda, S.
    Ciombor, K.
    Noonan, A.
    Hanna, W.
    Sehdev, A.
    Shaib, W.
    Mikhail, S.
    Neki, A.
    Oh, C.
    Li, Y. Z.
    Li, W.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [12] Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma.
    Ku, Geoffrey Yuyat
    Wu, Abraham Jing-Ching
    Trivedi, Nikhil
    Maron, Steven Brad
    Joshi, Smita Suhas
    Ilson, David H.
    Janjigian, Yelena Y.
    Shcherba, Marina
    Li, Jia
    Tang, Laura H.
    Yeh, Randy
    Sihag, Smita
    Park, Bernard J.
    Jones, David Randolph
    Molena, Daniela
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 355 - 355
  • [13] A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC)
    Dai, Guang-Hai
    Jia, Ru
    Si, Haiyan
    Wang, Zhi-Kuan
    Deng, Guo-Chao
    Zhang, Nan
    Liu, Fang-Fang
    Shi, Yue
    Zhang, Yao-Yue
    Jia, Yu-Shan
    Zhang, Bei
    Tong, Shuang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [14] MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
    Cassier, Philippe Alexandre
    Garin, Gwenaelle
    Eberst, Lauriane
    Delord, Jean-Pierre
    Chabaud, Sylvie
    Terret, Catherine
    Montane, Laure
    Bidaux, Anne-Sophie
    Laurent, Severine
    Jaubert, Lise
    Ferlay, Celine
    Bernardin, Mathilde
    Tabone-Eglinger, Severine
    Gilles-Afchain, Laurence
    Menetrier-Caux, Christine
    Caux, Christophe
    Treilleux, Isabelle
    Perol, David
    Gomez-Roca, Carlos Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [15] OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Geboes, Karen Paula
    Cassier, Philippe Alexandre
    Lambert, Aurelien
    Mitry, Emmanuel
    Prenen, Hans
    Pilla, Lorenzo
    Blanc, Jean-Frederic
    Gallego Jimenez, Inmaculada
    Cid, Roberto A. Pazo
    Rodriguez Garrote, Mercedes
    Feliu, Jaime
    Nordbladh, Karin
    Smith, Karin Enell
    Gomez Jimenez, David
    Ellmark, Peter
    Pico de Coa, Yago
    Ambarkhane, Sumeet Vijay
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [16] Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) plus nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    Shahda, Safi
    O'Neil, Bert H.
    Noonan, Anne M.
    Shaib, Walid Labib
    Hanna, Wahid Tewfik
    Mikhail, Sameh
    Neki, Anterpreet S.
    Chang, Yue
    Dai, Xiaoshu
    Li, Wei
    Brooks, Emily
    Oh, Cindy
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [17] Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).
    Bang, Yung-Jue
    Golan, Talia
    Lin, Chia-Chi
    Kang, Yoon-Koo
    Wainberg, Zev A.
    Wasserstrom, Heather
    Jin, Jin
    Mi, Gu
    McNeely, Samuel
    Laing, Naomi
    Goff, Laura Williams
    Fu, Siqing
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [18] Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
    Jia, Ru
    Si, Hai-Yan
    Wang, Zhi-Kuan
    Deng, Guo-Chao
    Zhang, Nan
    Liu, Fang-Fang
    Shi, Yue
    Zhang, Yao-Yue
    Jia, Yu-Shan
    Wang, Yanrong
    Fan, Meng-Jiao
    Miao, Meng-Meng
    Zhang, Bei
    Tong, Shuang
    Dai, Guang-Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 671 - 671
  • [19] A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.
    Weinberg, Benjamin Adam
    Wang, Hongkun
    Witkiewicz, Agnieszka Katarzyna
    Marshall, John
    Knudsen, Erik S.
    Pishvaian, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [20] Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)
    Hingorani, S. R.
    Bullock, A.
    Seery, T.
    Zheng, L.
    Sigal, D.
    Ritch, P. S.
    Braiteh, F. S.
    Zalupski, M.
    Bahary, N.
    Harris, W.
    Pu, J.
    Aldrich, C.
    Khelifa, S.
    Wu, W.
    Chondros, D.
    Jiang, P.
    Hendifar, A.
    ANNALS OF ONCOLOGY, 2017, 28
12345